SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): March 8, 2006.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
|
of
incorporation)
|
Identification
No.)
|
6121
Hollis Street
Emeryville,
California 94608
(Address
of principal executive offices)
(510)
350-2940
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Statements
made in this Report that are not historical facts may constitute forward-looking
statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties
include but are not limited to those discussed in this report and in BioTime's
Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” and similar expressions identify
forward-looking statements.
Section
5 Corporate
Governance and Management
Item
5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
Katherine
Gordon, a member of the Board of Directors, has informed BioTime that she
will
be retiring from the Board effective April 1, 2006 due to limitations on
her
available time. Ms. Gordon is a member of the audit committee, the compensation
committee, and the nominating committee of the Board of Directors.
Section
9-Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
99.1
|
Letter
from Katherine Gordon
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| BIOTIME, INC. | ||
| |
|
|
| Date: March 14, 2006 | By: | /s/ Steven Seinberg |
|
Steven Seinberg |
||
| Chief Financial Officer | ||
2
|
Exhibit
Number
|
Description
|
|
99.1
|
Letter
from Katherine Gordon
|
3
3/8/06
TO
BIOTIME'S BOARD OF DIRECTORS
Unfortunately,
because of limitations on my time, I will be stepping down from
BioTime's board effective April 1, 2006. I won't stand for reelection
at
the
next meeting.
It's
been
a pleasure serving on the board over the last several years.
Best
regards,
Katherine
Gordon